Keyword: Dana-Farber Cancer Institute
The Harvard researcher who first discovered the "exercise hormone" irisin reports it may be useful in bone formation.
Deerfield Management committed up to $80 million to fund a new center at the Dana-Farber Cancer Institute set on exploring protein degradation.
Eli Lilly doubles down on its collaboration with the Dana-Farber Cancer Institute, extending the partnership for another three years.
Chief Scientific Officer Andrew Phillips was named CEO of C4 Therapeutics, a 2016 Fierce 15 winner.
The thoracic oncologist will head up a team tasked with overseeing the advance of Lilly’s portfolio of immuno-oncology prospects.
Researchers are combining immunotherapies and attacking tumor defenses in efforts to improve checkpoint inhibitors.
Scientists at Dana-Farber Cancer Institute and Harvard have invented an immunotherapy “gel” that’s placed at the surgery site and is showing promising results in mouse models.
Novartis foresees next-generation immunotherapies that use biodegradable implants and injectable systems to trigger long-lasting attacks on tumors.
At the annual ASH meeting, oncologists at the Dana-Farber Cancer Institute demonstrated how simple blood tests may hold promise for managing multiple myeloma.
